Chromosome number and carmustine sensitivity in human gliomas

Area of Science:

• Neuro-oncology
• Cancer Cytogenetics
• Chemotherapy Resistance

Background:

• Malignant gliomas often develop resistance to chemotherapy agents like BCNU (carmustine).
• Distinguishing intrinsic chemoresistance from acquired resistance is crucial for effective treatment strategies.
• This study investigates the relationship between glioma chromosomal complements and BCNU sensitivity.

Purpose of the Study:

• To correlate the cytogenetic profiles of freshly resected human gliomas with their sensitivity to BCNU.
• To determine if specific chromosomal abnormalities predict response or resistance to BCNU treatment.
• To inform strategies for overcoming or preventing chemoresistance in malignant gliomas.

Main Methods:

• Single-cell dissociation of 31 human gliomas (astrocytomas, anaplastic astrocytomas, glioblastomas multiforme).
• Cytogenetic analysis to determine chromosomal complements (ploidy, marker chromosomes).
• BCNU sensitivity testing using the colony-forming assay (CFA) on first-division cells.

Main Results:

• Near-diploid gliomas (predominantly 2n+/- cells) consistently showed resistance to BCNU.
• Hyperdiploid gliomas (3n+/- and 4n+/- populations, >60% cells with ≥60 chromosomes) demonstrated sensitivity to BCNU.
• Sensitive gliomas exhibited extensive ploidy changes, multiple clonal populations, and 1-8 clonal marker chromosomes; resistant tumors had fewer such abnormalities.

Conclusions:

• BCNU (carmustine) is most effective against hyperdiploid glioma cells with complex karyotypic deviations.
• Near-diploid glioma cell populations with limited chromosomal changes are characteristic of BCNU resistance.
• Cytogenetic analysis of freshly resected gliomas can predict BCNU sensitivity, aiding in treatment selection.